+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Erythropoietin Drugs Market by Product Type and Application: Global Opportunity Analysis and Industry Forecast, 2021-2028

  • PDF Icon


  • 165 Pages
  • May 2021
  • Region: Global
  • Allied Market Research
  • ID: 5394266
The erythropoietin drugs market was valued at $9,243.12 million in 2020, and is projected to reach $ 14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028.

Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin-alfa, epoetin-beta, darbepoetin-alfa, epoetin-omega, and epoetin-delta.

Rise in number of patients suffering from anemic conditions induced due to cancer, HIV and ESRD treatment, favorable reimbursements, and increase in commercialization of EPO biosimilars are the major factors for the market growth. However, side effects such as arterial hypertension, iron deficiency, influenza-like syndrome, and longer treatment period (4-6 weeks) hampers growth of erythropoietin drugs market. Availability of numerous biosimilars has rendered low-cost options for patients, therefore, increased adoption rates for EPO drugs particularly in developing regions, which boosts the market growth. Furthermore, commercialization patterns for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and awareness regarding benefits of EPO therapeutics contribute toward growth of erythropoietin drugs market.

The global erythropoietin drugs market is segmented into product type, application, and region. On the basis of product type, the market is categorized into epoetin-alfa, epoetin-beta, darbepoetin alfa. By application, it is classified into anemia, kidney disorders, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits for Stakeholders

  • The study provides an in-depth analysis of the global erythropoietin drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of erythropoietin used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.


By Type

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin alfa

By Application

  • Anemia
  • Kidney Disorders
  • thers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

List of Key Players profiled in the report

  • Amgen Inc.
  • Biocon,
  • Celltrion, Inc.
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Hospira Inc.
  • Intas Pharmaceuticals
  • LG Life Sciences Ltd.
  • Roche
  • Ranbaxy Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary Research
1.4.3. Analyst tools and models
2.1. Key findings of the study
2.2. CXO perspective
3.1. Market definition and scope
3.2. Clinical trials for EPO drug
3.3. Market share analysis, 2020
3.4. Market dynamics
3.4.1. Drivers Increasing number cases: including cancer,HIV, kidney disease and anaemia Growing trends of commercialization for erythropoietin biosimilars Increasing level of awareness about the benefits of EPO therapeutics
3.4.2. Restraints Unaffordability of therapeutics Longer duration of treatments Adverse amount of side effects
3.4.3. Opportunities Commercialization of Darbepoetin alfa biosimilar Achieving Economies of scale across developed region with biosimilar version of EPO
3.5. Impact of Covid-19 on Erythropoietin Drug Market
4.1. Epoetin-alfa
4.1.1. Key market trends and opportunities
4.1.2. Market size and forecast
4.1.3. Market analysis, by country
4.2. Epoetin-beta
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Darbepoetin-alfa
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Other
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
5.1. Hematology
5.1.1. Market size and forecast
5.1.2. Market analysis, by country
5.2. Kidney Disorders (ESRD and Dialysis)
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Cancer
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
6.1. North America
6.1.1. Key market trends & opportunities
6.1.2. Market size and forecast
6.2. Europe
6.2.1. Key market trends & opportunities
6.2.2. Market size and forecast
6.3. Asia-Pacific
6.3.1. Key market trends & opportunities
6.3.2. Market size and forecast
6.4. LAMEA
6.4.1. Key market trends & opportunities
6.4.2. Market size and forecast
7.1.1. Company overview
7.1.2. Amgen Inc. snapshot
7.1.3. Operating Business Segment
7.1.4. Financial performance
7.2.1. Company overview
7.2.2. Johnson & Johnson snapshot
7.2.3. Operating Business Segment overview
7.2.4. Financial performance
7.3.1. Company overview
7.3.2. Roche Diagnostics snapshot
7.3.3. Operating Business Segment Overview
7.3.4. Financial performance
7.4.1. Company overview
7.4.2. Hospira Inc. snapshot
7.4.3. Operating business segment
7.4.4. Financial performance
7.4.5. Key Strategies move & development
7.5.1. Company overview
7.5.2. LG Life Sciences Ltd. snapshot
7.5.3. Operating Business segment overview
7.5.4. Financial performance
7.6.1. Company overview
7.6.2. Biocon snapshot
7.6.3. Operating Business Segment Overview
7.6.4. Financial performance
7.6.5. Key Strategies move and development
7.7.1. Company overview
7.7.2. Intas Pharmaceuticals snapshot
7.7.3. Operating Business Segment Overview
7.7.4. Financial performance
7.8.1. Company overview
7.8.2. Teva Pharmaceutical Industries Ltd. snapshot
7.8.3. Operating business segment overview
7.8.4. Financial performance
7.9.1. Company overview
7.9.2. Ranbaxy Laboratories Ltd. snapshot
7.9.3. Operating business segment overview
7.9.4. Financial performance
7.10.1. Company overview
7.10.2. Celltrion, Inc. snapshot
7.10.3. Financial performance
List of Tables
Table 01. Clinical Trials of Erythropoeitin for Neural Diseases and Wound Healing
Table 02. Global Erythropoietin Drug Market by Product Types, 2020-2028($Million)
Table 03. Global Erythropoietin Alfa Drugs Market by Geography, 2020-2028($Million)
Table 04. Global Erythropoietin Beta Drugs Market by Geography, 2020-2028($Million)
Table 05. Global Darbepoetin Alfa Drugs Market by Geography, 2020-2028($Million)
Table 06. Global Other Drugs Market by Geography, 2020-2028($Million)
Table 07. Global Erythropoietin Market by Applications, 2020-2028($Million)
Table 08. Global Hematology Application Market by Geography, 2020-2028, $Million
Table 09. Global Esrd and Dialysis Induced Anemia Erythropoietin Drugs Application Market by Geography, 2020-2028, $Million
Table 10. Global Cancer Application Market by Geography, 2020-2028, $Million
Table 11. Global Others Application Market by Geography, 2020-2028, $Million
Table 12. Global Erythropoetin Market by Geography, 2020 - 2020 ($Million)
Table 13. North America Erythropoetin Market by Product Types, 2020 - 2020 ($Million)
Table 15. Europe Erythropoetin Market by Product Types, 2020 - 2020 ($Million)
Table 17. Asia-Pacific Erythropoetin Market by Product Types, 2020 - 2020 ($Million)
Table 18. LAMEA Erythropoetin Market by Product Types, 2020 - 2020 ($Million)
Table 19. Amgen Inc. Snapshot
Table 20. Amgen Inc. Operating Business Segment
Table 21. Johnson & Johnson Snapshot
Table 22. Johnson and Johnson Operating Segements
Table 23. Roche Diagnostics Snapshot
Table 24. Roche Diagnostics Operating Segements
Table 25. Hospira Inc. Snapshot
Table 26. Hospira Inc. Operating Segements
Table 27. Lg Life Sciences Ltd. Diagnostics Snapshot
Table 28. Lg Life Sciences Ltd. Diagnostics Operating Segements
Table 29. Biocon Snapshot
Table 30. Biocon Operating Segements
Table 31. Intas Pharmaceuticals Snapshot
Table 32. Intas Pharmaceuticals Operating Segements
Table 33. Teva Pharmaceutical Industries Ltd. Snapshot
Table 34. Teva Pharmaceutical Industries Ltd. Operating Segements
Table 35. Ranbaxy Laboratories Ltd. Snapshot
Table 36. Celltrion, Inc. Snapshot
List of Figures
Figure 01. Global Erythropoietin (Epo) Drugs Market Definition
Figure 02. Market Share Analysis of Global Erythropoietin Drugs Market (2020)
Figure 03. Financial Revenue of Amgen Inc. by Geography (2020)
Figure 04. Financial Revenue of Amgen Inc. by Product Portfolio (2020)
Figure 05. SWOT Analysis of Amgen Inc.
Figure 06. Financial Revenue of Johnson & Johnson by Geography (2020)
Figure 07. Financial Revenue of Johnson & Johnson by Business Units(2020)
Figure 08. SWOT Analysis of Johnson & Johnson
Figure 09. Financial Revenue of Roche Diagnostics by Geography (2020)
Figure 10. Financial Revenue of Roche Diagnostics by Business Units (2020)
Figure 11. SWOT Analysis of Roche Diagnostics
Figure 12. Financial Revenue of Hospira Inc. by Geography (2020)
Figure 13. Financial Revenue of Hospira Inc. by Business Units (2020)
Figure 14. SWOT Analysis of Hospira Inc.
Figure 15. Net Revenue Generation (2011-2020)
Figure 16. SWOT Analysis of Lg Life Sciences Ltd.
Figure 17. Revenue Generated by Business Units (2020)
Figure 18. SWOT Analysis of Biocon
Figure 19. SWOT Analysis of Intas Pharmaceuticals
Figure 20. Net Revenue Generation by Geography (2020)
Figure 21. Net Revenue Generation by Businesses (2020)
Figure 22. SWOT Analysis of Teva Pharmaceutical Industries Ltd.
Figure 23. Key Financials of Ranbaxy Laboratories Limited by Geography (2014)
Figure 24. SWOT Analysis of Ranbaxy Laboratories Ltd.
Figure 25. Net Profit During 2011-2020
Figure 26. SWOT Analysis of Celltrion, Inc.

Companies Mentioned

  • Amgen Inc.
  • Johnson & Johnson
  • Hospira Inc.
  • Roche
  • LG Life Sciences Ltd.
  • Biocon
  • Intas Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Ranbaxy Laboratories Ltd.
  • Celltrion Inc


The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.


Table Information